GlossaryCompound ClassLongevity Peptide
Compound Class

Longevity Peptide

Also known as: anti-aging peptide · healthspan peptide

'Longevity peptide' is an informal label for peptides promoted to slow aging, such as Epitalon, MOTS-c and SS-31; evidence is mostly from cells and animals.

"Longevity peptide" is a marketing category, not a drug class, and the compounds placed in it act on unrelated biology. Epitalon is promoted for effects on telomerase, the enzyme that maintains the ends of chromosomes (telomeres). MOTS-c is a peptide encoded in mitochondrial DNA. SS-31, also called elamipretide, binds cardiolipin in the inner mitochondrial membrane.

The evidence behind each is mostly preclinical. For Epitalon, a 2003 study added the peptide to cultures of human fetal fibroblasts that lacked telomerase and reported telomerase activity and telomere elongation. For MOTS-c, a 2021 study found it enhanced physical performance in young, middle-aged, and old mice, and that intermittent treatment started late in life increased physical capacity; in people, the same study found that exercise raises the body's own MOTS-c levels in muscle and blood. None of these results shows a longer or healthier life in humans.

Why it matters

Cell and mouse results do not tell you whether a compound extends healthy life in people. Elamipretide shows how hard the human step is. On September 19, 2025, FDA granted it accelerated approval for Barth syndrome, a rare inherited mitochondrial disease, yet its randomized, placebo-controlled crossover trial showed no significant improvement in the 6-minute walk test or in fatigue scores. Benefits were reported later, in a 168-week open-label extension, and a confirmatory trial is required. It is approved for that disease, not for aging.

Aging is also slow to measure. There is no short-term test that shows you have aged less, so longevity claims usually lean on markers such as telomerase activity or blood tests, and a change in a marker is not the same as a longer or healthier life. A protocol you run for months, with no meaningful endpoint, can feel like it is working simply because nothing bad happened.

How to evaluate a longevity claim

  1. Identify the model: cultured cells, mice, or people.
  2. Identify the outcome: a marker (such as telomerase activity) or a clinical result (function, disease, survival).
  3. Check whether the compound has an approved use, and for what condition, before assuming any of its evidence applies to aging.
  4. If you track markers yourself, use the same lab and the same conditions each time so changes are comparable.

Common mistakes

  • Treating telomerase activity in a cell culture as evidence of longer life in people.
  • Citing mouse performance or healthspan results as if they applied directly to humans.
  • Pointing to elamipretide's approval for Barth syndrome as evidence that it slows aging.
  • Tracking many markers at once and reading random movement in any one of them as a real effect.
  • Assuming a compound is low-risk for long-term use because it is described as natural or mitochondrial.

Sources

  1. Preclinical studyEpithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 2003. PMID 12937682.
  2. Preclinical studyMOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 2021. PMID 33473109.
  3. ReviewElamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. Drug Discov Ther, 2026. PMID 41260682.

Page updated . How we grade evidence: methodology.

Related Terms

Mitochondrial Biogenesis

Mitochondrial biogenesis is the process by which cells build new mitochondria, increasing their capacity to produce energy through respiration.

Telomerase Activation

Telomerase activation means switching on telomerase, the enzyme that adds DNA to chromosome ends (telomeres), offsetting their shortening as cells divide.

Growth Hormone Secretagogue

A growth hormone secretagogue (GHS) is a compound that makes the pituitary release its own growth hormone, usually by activating the ghrelin receptor.

GHRH Analog

A GHRH analog is a modified growth hormone-releasing hormone that activates the GHRH receptor on the pituitary to release the body's own growth hormone.

Look up any peptide term inside DoseCraft Pro

The glossary is just the start. Inside DoseCraft you get 90+ compound deep-dives, a PK-aware protocol engine, interaction checker, and vendor trust scores — every term surfaced in protocol-design context, not a separate page.

Start Free Trial